⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Sri Krishna Pharmaceuticals Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Sri Krishna Pharmaceuticals Limited
↗Hyderabad, India
Sri Krishna Pharmaceuticals Limited (SKPL) is a prominent, vertically integrated Indian pharmaceutical company established in 1974. It specializes in the bulk manufacture of Active Pharmaceutical Ingredients (APIs), Direct Compression (DC) granules, and finished dosage forms, with a historical legacy as a pioneer in paracetamol production.
The company operates five manufacturing facilities in India, primarily in Telangana and Maharashtra, and maintains a global presence by supplying niche drugs and intermediates to international markets. SKPL is recognized for its compliance with stringent global regulatory standards, including USFDA, EDQM, and others, and focuses on contract manufacturing (CDMO) services alongside its proprietary product portfolio.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$60M-$120M
Founded:1974
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Global generic pharmaceutical companies (CDMO services)
COMPETITION
Position:Niche Player
Competitors:Aurobindo Pharma, Hetero Labs, Mylan Laboratories, Divi's Laboratories
LEADERSHIP
Key Executives:
Venkata Subba Reddy Vempalle - Director
Nikhil Bihari Pandey - Chief Financial Officer
Scientific Founders:Dr. V. V. Subba Reddy
LINKS
Website:srikrishnapharma.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sri Krishna Pharmaceuticals Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.